Yoshino S, Tabata T, Hazama S, Iizuka N, Yamamoto K, Hirayama M, Tangoku A, Oka M
Department of Surgery II, Yamaguchi University School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
Anticancer Res. 2000 Nov-Dec;20(6C):4707-11.
Recent studies demonstrated that patients with advanced cancer may have impaired cell-mediated immunity caused by an imbalance between Th1 and Th2 responses. We evaluated the ability of lentinan (LNT) to modulate Th1 and Th2 responses in patients with digestive cancers.
Peripheral blood samples were collected preoperatively from 28 patients with digestive cancers before and after intravenous administration of LNT (2 mg x 3 times/week). The proportions of CD4+ T-cells producing intracellular cytokines were determined with flow cytometry.
After LNT treatment, CD4+ IFN-gamma+ T-cell percentages increased significantly (p < 0.05), whereas CD4+ IL-4+ T-cell and CD4+ IL-6+ T-cell percentages decreased significantly (p < 0.02). No significant change occurred in proportions of CD4+ IL-10+ T-cells. The after/before LNT treatment percentages ratio of CD4+ IFN-gamma+ T-cells correlated negatively with that of CD4+ IL-4+ T-cells (p < 0.01). The after/before treatment percentage ratio of CD4+ IL-4+ T-cells correlated positively with that of CD4+ IL-6+ T-cells (p < 0.05).
LNT apparently can cancel Th2-dominant condition in patients with digestive cancers and may improve the balance between Th1 and Th2.
近期研究表明，晚期癌症患者可能因Th1和Th2反应失衡而导致细胞介导免疫受损。我们评估了香菇多糖（LNT）对消化系统癌症患者Th1和Th2反应的调节能力。
术前采集28例消化系统癌症患者静脉注射LNT（2mg×3次/周）前后的外周血样本。采用流式细胞术测定产生细胞内细胞因子的CD4 + T细胞比例。
LNT治疗后，CD4 + IFN-γ+ T细胞百分比显著增加（p < 0.05），而CD4 + IL-4 + T细胞和CD4 + IL-6 + T细胞百分比显著降低（p < 0.02）。CD4 + IL-10 + T细胞比例无显著变化。LNT治疗后/治疗前CD4 + IFN-γ+ T细胞百分比比值与CD4 + IL-4 + T细胞百分比比值呈负相关（p < 0.01）。治疗后/治疗前CD4 + IL-4 + T细胞百分比比值与CD4 + IL-6 + T细胞百分比比值呈正相关（p < 0.05）。
LNT显然可以消除消化系统癌症患者Th2主导的状态，并可能改善Th1和Th2之间的平衡。
